Back to Search
Start Over
Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
- Source :
-
Formulary (Cleveland, Ohio) [Formulary] 1995 Sep; Vol. 30 (9), pp. 532-4, 542. - Publication Year :
- 1995
-
Abstract
- Women with large uterine leiomyomas traditionally have had just one choice for therapy--abdominal hysterectomy. Recently, gonadotropin-releasing hormone (GnRH) agonist therapy has been introduced as an option to shrink tumors before surgery. When administered preoperatively, usually for 2 months, GnRH therapy has been shown to reduce tumor size enough to permit an endoscopic myomectomy or a vaginal hysterectomy. It has also been shown to reduce blood loss associated with the tumors and increase hemoglobin levels. When assessed for its economic impact, preoperative GnRH therapy reduces both direct and indirect costs associated with a hysterectomy.
- Subjects :
- Adult
Antineoplastic Agents, Hormonal economics
Combined Modality Therapy
Female
Gonadotropin-Releasing Hormone agonists
Humans
Hysterectomy economics
Hysterectomy methods
Leiomyoma economics
Leiomyoma surgery
Length of Stay economics
Leuprolide economics
Megestrol economics
Megestrol therapeutic use
Megestrol Acetate
Sick Leave economics
United States
Uterine Neoplasms economics
Uterine Neoplasms surgery
Antineoplastic Agents, Hormonal therapeutic use
Cost Savings statistics & numerical data
Drug Costs statistics & numerical data
Leiomyoma drug therapy
Leuprolide therapeutic use
Megestrol analogs & derivatives
Uterine Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1082-801X
- Volume :
- 30
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Formulary (Cleveland, Ohio)
- Publication Type :
- Academic Journal
- Accession number :
- 10161243